Sonidegib diphosphate, also known as Erismodegib diphosphate, is a potent and selective Smoothened (Smo) antagonist. It works by directly interacting with Smo to reduce the expression of downstream Hedgehog (Hh) signaling targets. This compound has shown dose-related antitumor activity in medulloblastoma mouse models, effectively inhibiting tumor growth and causing regression at higher doses. It is for research use only.
- Potent and selective Smo antagonist
- Interacts directly with Smo to reduce expression of downstream Hh signaling targets
- Inhibits the Hh pathway in CD34+ chronic phase chronic myeloid leukemia (CML) cells
- Reduces the number and self-renewal capacity of CML leukemia stem cells (LSC)
- Demonstrates dose-related antitumor activity in medulloblastoma allograft mouse models
- Significantly inhibits tumor growth and affords regression at higher doses